Koyfin Home > Directory > Health Care > Bristol-Myers Squibb Company > Long-term Debt / Equity

Bristol-Myers Squibb Company Long-term Debt / Equity Chart (BMY)

Bristol-Myers Squibb Company annual/quarterly Long-term Debt / Equity from 2010 to 2020.
  • Bristol-Myers Squibb Company Long-term Debt / Equity for the quarter ending September 09, 2020 was $84m a -1.72% decrease of -1m year over year
  • Bristol-Myers Squibb Company Long-term Debt / Equity for the last 12 months ending September 09, 2020 was $84m a -1.72% decrease of -1m year over year
  • Bristol-Myers Squibb Company Annual Long-term Debt / Equity for 2019 was $85m a 52.98% increase of 45m from 2018
  • Bristol-Myers Squibb Company Annual Long-term Debt / Equity for 2018 was $40m a -46.92% decrease of -19m from 2017
  • Bristol-Myers Squibb Company Annual Long-term Debt / Equity for 2017 was $59m a 40.61% increase of 24m from 2016
Other Ratios Metrics:
  • Bristol-Myers Squibb Company Total Debt / Capital for the quarter ending December 12, 2018 was $35m a -7.68% decrease of -3m year over year
  • Bristol-Myers Squibb Company Other Liabilities for the quarter ending September 09, 2018 was $4,603m a -12.23% decrease of -563m year over year
  • Bristol-Myers Squibb Company Total Debt / Equity for the quarter ending December 12, 2018 was $53m a -12.27% decrease of -7m year over year
View Chart On Koyfin

Quarterly BMY Long-term Debt / Equity Data

09/2020$84m
06/2020$87m
03/2020$87m
12/2019$85m
09/2019$140m
06/2019$154m
03/2019$40m
12/2018$40m
09/2018$41m
06/2018$46m

Annual BMY Long-term Debt / Equity Data

2019$85m
2018$40m
2017$59m
2016$35m
2015$45m
2014$48m
2013$53m
2012$48m
2011$34m
2010$34m